IRADIMED stock reaction and recent performance

IRADIMED (IRMD) has been drawing attention after recent trading volatility, with the stock down 2.4% over the past day and 3.3% over the past week, while still posting a 1 year total return above 50%.

Recent trading has been choppy, with the 1 month share price return up 3.1% but the 3 month share price return down 14.5%. The 1 year total shareholder return of 52.4% points to momentum that has cooled in the short term as expectations and perceived risks are reassessed around the current US$89.86 share price and broader valuation debate.

If IRADIMED’s recent swings have you thinking about where else growth and risk might line up differently, this is a good moment to scan 39 healthcare AI stocks

With IRADIMED posting a 1-year total return above 50%, an annual revenue growth rate near 10%, and a share price that sits below a US$118 analyst target, is the stock undervalued, or is future growth already priced in?

Most Popular Narrative: 24.3% Undervalued

With IRADIMED last closing at $89.86 against a widely followed fair value of $118.67, the prevailing narrative sees a clear valuation gap built on specific operating and margin assumptions.

The pricing power associated with the new 3870 pump-management, which expects a ~12% higher average selling price than the older model, should directly support higher gross margins, while the company's demonstrated ability to maintain ~78% gross margin yields operating leverage, boosting both net margins and earnings per share as the business scales.

Want to see what kind of revenue climb and margin profile that quote is plugged into? The narrative leans on steady volume growth, richer pricing, and a premium earnings multiple to bridge today’s price to that $118.67 fair value call.

Result: Fair Value of $118.67 (UNDERVALUED)

However, this hinges on a narrow product line and extended pump backlogs, so any supply chain issues or slower hospital spending could quickly challenge that upside case.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another View: Market Multiples Flash A Different Signal

While the analyst narrative points to a fair value of $118.67, the current P/E of 48.7x tells a tougher story. It stands well above the US Medical Equipment industry at 24.2x, peers at 36.5x, and even a fair ratio of 18.9x that the market could move toward over time.

That gap points to clear valuation risk if sentiment cools. The real question is whether IRADIMED’s growth and margins can keep investors comfortable paying such a premium.

Next Steps

With sentiment clearly split between growth optimism and valuation risk, it makes sense to review the underlying data and decide where you stand. If you want a focused view on what the market currently sees as the upside case for IRADIMED, take a closer look at the 2 key rewards

Looking for more investment ideas?

IRADIMED might be on your radar, but you do not want to miss other opportunities that match different goals, risk levels, and income needs.

• Target potential mispricing by scanning screener containing 22 high quality undiscovered gems that combine solid fundamentals with limited market attention.
• Prioritise resilience by reviewing 63 resilient stocks with low risk scores that score well on financial strength and business stability.
• Build income potential by checking 10 dividend fortresses offering higher yields with an emphasis on durability.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.